Finanzen von ASP Isotopes Inc. (ASPI)ASPIASP Isotopes Inc.

ASP Isotopes Inc. (ASPI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Specialist isotopes and related services, accounting for 81.0% of total sales, equivalent to $3.39M. Other significant revenue streams include Helium and LNG and Nuclear fuels. Understanding this composition is critical for investors evaluating how ASPI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, ASP Isotopes Inc. maintains a gross margin of 28.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -667.48%, while the net margin is -663.54%. These profitability ratios, combined with a Return on Equity (ROE) of -104.60%, provide a clear picture of how effectively ASPI converts its operational activities into shareholder value.

In the context of the broader market, ASPI competes directly with industry leaders such as EIKN and BLSM. With a market capitalization of $654.63M, it holds a leading position in the sector. When comparing efficiency, ASPI's gross margin of 28.89% stands against EIKN's N/A and BLSM's N/A. Such benchmarking helps identify whether ASP Isotopes Inc. is trading at a premium or discount relative to its financial performance.

ASP Isotopes has shown significant revenue growth, with Q2 2026 revenue at $4,523,000, up from $1,166,524 in Q4 2024. However, net income remains negative, with a loss of $33,993,000 in Q2 2026, and gross margin fluctuating, currently at 19.46%.